Compare SPCE & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | GBIO |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.3M | 36.3M |
| IPO Year | N/A | 2020 |
| Metric | SPCE | GBIO |
|---|---|---|
| Price | $3.20 | $5.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $9.22 | $8.88 |
| AVG Volume (30 Days) | ★ 6.0M | 65.1K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,661,000.00 | ★ $15,270,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,656.89 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.18 | $3.00 |
| 52 Week High | $6.74 | $12.40 |
| Indicator | SPCE | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 60.89 |
| Support Level | $3.08 | $5.40 |
| Resistance Level | $3.33 | $5.69 |
| Average True Range (ATR) | 0.27 | 0.22 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 23.66 | 87.72 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.